Navigation Links
AstraZeneca Receives Complete Response Letter From US FDA For BRILINTA™ (Ticagrelor Tablets)
Date:12/16/2010

WILMINGTON, Del., Dec. 16, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA™).

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO)

In the CRL, the FDA requested additional analyses of the PLATO data. The agency did not request that additional studies, including clinical studies, be conducted as a prerequisite for approval of the ticagrelor NDA.

AstraZeneca is evaluating the contents of the CRL and will respond to the agency's request for additional analyses of the PLATO data as soon as possible. The company remains confident in the NDA submission for ticagrelor and in its ability to respond to the agency's questions.

"Our highest priority is to provide the requested PLATO analyses to the FDA and progress to completion of the BRILINTA NDA review," said Martin Mackay, President, Research & Development, AstraZeneca.

NOTES TO EDITORS

About BRILINTA™ (ticagrelor tablets)

BRILINTA is an oral antiplatelet treatment for acute coronary syndromes (ACS). BRILINTA is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclopentyltriazolopyrimidines (CPTPs). BRILINTA is the first reversibly-binding oral ADP receptor antagonist.

BRILINTA is currently under regulatory review in eighteen territories around the world and was granted marketing authorization under the trade name BRILIQUE™ by the European Commission (EC) on December 6, 2010.

BRILINTA and BRILIQUE are trademarks of the AstraZeneca group of companies.

About the PLATO study

PLATO was a large (18,624 patients in 43 countries) head-to-head patient outcomes study of ticagrelor versus clopidogrel, designed to establish whet
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... New York , August 4, 2015 ... report titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, ... and Others) - Global Industry Analysis, Size, Volume, Share, ... According to a new market report published by ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ...
(Date:8/4/2015)... BioElectronics Corporation (OTC Pink: BIEL), the ... medical devices, announced today that its registry study ... device has been published in the prominent peer ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain sufferers ... Chronic pain is a major ...
(Date:8/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ) has announced the ... (Household & Personal Care, Pharmaceutical, Oilfield, Agrochemicals, and Others) ... report to their offering. The market ... in 2014 and is projected to grow at a ... data mentioned in the report is based on the ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3
... America,s Specialty Medicines Companies (ASMC), an informal working group ... concerns about H.R. 3962, the "Affordable Health Care for ... These smaller companies fear that the cumulative effect of ... their efforts to bring new medicines to market. ...
... Nov. 6 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... President and Chief Financial Officer, effective November 9, 2009. ... Team updates. , "Michael will be an excellent complement ...
Cached Medicine Technology:Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5
(Date:8/4/2015)... Denver, CO (PRWEB) , ... August 04, 2015 ... ... for skilled nursing homes and other long-term care facilities, today announced details of ... (QAPI) for nursing homes and centers. , Providigm’s QAPI Accreditation program , ...
(Date:8/4/2015)... ... August 04, 2015 , ... A new report by ... reseller channel will grow at least 6 percent in 2015, as solution providers ... greater than their OEM/vendor partners. , The 2112 Group’s 2015 Midyear Channel ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills ... end to driving, says the August 2015 Harvard Health Letter. , "Age and ... It requires an individual assessment of skills," says Lissa Kapust, a social worker ...
(Date:8/4/2015)... ... , ... Updated enrollment data on the top U.S. health plans, as collected ... http://www.AISHealth.com . The data is free to all registered users to AISHealth.com. Based ... on the website’s “Data” section include:, , Top 25 U.S. ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... The ... designed to treat Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were ... Academy of Ophthalmology. According to the results of the trial, the implant, more commonly ...
Breaking Medicine News(10 mins):Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2
... In March, AHIP,s Board of,Directors advocated for ... and Medicare Part D plan marketing activities. Today,the ... new regulations., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), ... beneficiaries can rely on the,information being provided to ...
... countless years of collective brainpower to rescuing princesses or ... at the University of Washington will try to harness ... even finding a cure for HIV., A new game, ... Introductory levels teach the rules, which are the same ...
... DALLAS, May 8 May has been designated Allergy ... working to educate,Americans about the conditions. Of most importance ... but especially when the environment indoors or,outdoors may trigger ... 3,800 asthma-related deaths in the,United States. The American Association ...
... Software training supplements counseling, could also treat other ... -- The use of a computer-assisted training program, ... stay abstinent longer than counseling alone, a Yale ... , The trial included 77 people who sought ...
... Calif., May 8 As injectable fillers,become mainstream ... longer lasting,and less expensive alternatives to prevent facial ... busy practice in,Beverly Hills says, "Fillers such as ... suture material. When injected into,human tissue, all of ...
... May 8 Metametrix Clinical Laboratory (, ... and metabolic testing,announced the introduction of the ... the oxidative products of,tetrahydrobiopterin (BH4)., Neopterin ... reactions,involving tetrahydrobiopterin (BH4). Restricted BH4 availability has ...
Cached Medicine News:Health News:Computer game's high score could earn the Nobel Prize in medicine 2Health News:Computer game's high score could earn the Nobel Prize in medicine 3Health News:Computer game's high score could earn the Nobel Prize in medicine 4Health News:Respiratory Therapists Offer Breath of Fresh Air During Allergy & Asthma Month 2Health News:Computer Program Helps Drug Abusers Stay Clean 2Health News:Dr. Arnold Klein Warns of Dangers With Permanent and Longer Lasting Injectable Fillers 2Health News:Metametrix Introduces the New Neopterin/Biopterin Profile 2
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours....
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
Medicine Products: